A pilot external quality assurance (EQA) survey for the free light chain (FLC) assay was developed and implemented in Korea. Methods: Survey data over 6 years (2010)(2011)(2012)(2013)(2014)(2015) were collected retrospectively and Sigma metrics were calculated for method-specific peer groups. Results: Nineteen to 29 laboratories participated in the EQA survey, and nephelometric (20%) and turbidi metric (80%) methods were used. Using a previously published clinically relevant reference change value (RCV) of 54.5% as the tolerance limit, the method-specific median Sigma metrics of kappa (κ) and lambda (λ) FLC achieved greater than Three-Sigma for 86-97% of all EQA distributions, and Five-Sigma for 48-72% of all distributions. Conclusions: This EQA analysis of FLC assay applied clinically relevant quality specifications using Sigma metrics. During the 6-year EQA survey, we found that most of the results from participating laboratories meet clinically relevant quality specifications. In addition, method-specific differences were noted for λ FLC, at FLC concentrations above the initial measuring range that require a sample dilution.
Introduction
Free light chain (FLC) assays quantitatively measure light chains that are not bound to immunoglobulin heavy chains, and detect clonal restriction through a skewed ratio of free kappa (κ) to free lambda (λ) light chains [1] . The assay uses polyclonal antibodies that bind exclusively to the hidden epitopes of FLC molecules located at the junction of the immunoglobulin heavy and light chains in an intact immunoglobulin. These epitopes are only accessible when the light chain molecules are not bound to the heavy chain, which makes the assay highly specific. The use of latex enhancement further enhances the sensitivity of the assay to a few mg/L, and the assay can be performed by turbidimetry or nephelometry on a number of automated laboratory instruments.
The FLC assay has become standard practice and is recommended in various guidelines for diagnosis, prognostic assessment and evaluation of patient response to treatment in multiple myeloma and related plasma cell disorders [2] [3] [4] [5] [6] . However, technical concerns with the FLC assay include non-linearity and antigen excess, FLC polymerization, possibility of undetected "private" epitopes, lack of international standards, lot-to-lot variability of the reagent and inter-instrument variability.
In this regard, an external quality assurance (EQA) survey for the quantitative FLC assay was developed and implemented in collaboration with the Quality Assurance Committee of the Korean Society for Laboratory Medicine. We analyzed the 6-year EQA survey data and applied Sigma metrics to evaluate the observed analytical characteristics of the FLC assay and to assess the quality of the FLC assay that is being achieved.
Materials and methods

Preparation of EQA materials and design of the EQA survey
The EQA material was derived from surplus serum from patients with monoclonal gammopathies and from healthy controls, and a serum pool was prepared as described in the Clinical and Laboratory Standards Institute document C37-A [7] . FLC concentrations were titrated to examine medical decision points, linearity, antigen excess and lower limit of quantitation. Serum material manufactured for quality assurance (QA) measures (Binding Site, Birmingham, UK) and commercial quality control (QC) materials purchased from Randox (Randox, Antrim, UK) were also used.
Three levels of EQA specimens were distributed biannually to the participating laboratories. The specimens were shipped frozen with ice pack and were transported by registered mail. Instructions regarding the correct processing of the specimens upon receipt, care needed for reconstruction, storage, and deadlines for sample analysis and reporting were provided with each dispatch of EQA materials. For each sample, the participating laboratory reported the ᴋ and λ FLC results and the ᴋ/λ ratios. The participating laboratories were given a unique laboratory code known only to the EQA coordinator, staff and the laboratory, for anonymization and confidentiality.
Two types of reports were provided for each level of EQA material. One was a summary report with the mean, standard deviation (SD) and standard deviation index (SDI) of all participant results. SDI expresses the reported result as the number of SDs it is from the mean value (SDI = [result - mean]/SD).
The other report was specific to each method peer group. Due to the lack of an international standard material or a reference measurement procedure for FLC, the FLC EQA was designed as a consensus program with major performance goals (criteria) based on the laboratory consensus. For each type of EQA report, the mean of all participants' results and the mean of each method peer group results were regarded as the target values, respectively. Those results distributed more than 3 SD away from the mean were regarded as outliers and removed from statistical analyses [8] .
Application of Sigma metrics and statistical analysis of FLC EQA survey data
Survey data from 32 EQA samples distributed in 11 EQA surveys over 6 years (from 2010 to 2015) were collected retrospectively. An Excel spreadsheet was used to tabulate the observed means, SDs and medians for the method subgroups to calculate observed bias, coefficient of variation (CV), total error (TE) and Sigma metrics, and to plot %bias and %CV for each subgroup for each specimen in each episode on the Sigma Proficiency Assessment Chart [9] . Sigma metrics were calculated as follows [9] : Due to the small number of laboratories comprising specific instrument peer groups, and for a simplified analysis, only method-specific peer groups were defined. The method-specific bias was estimated as the difference from the weighted average. The weighted average was calculated to account for the number of laboratories in each method subgroup [9] . Due to the lack of a well-established consensus definition of quality requirements regarding the FLC assay, multiple surrogate definitions of quality requirements were assessed ( Table 1 ). The Sigma Proficiency Assessment Chart was developed using a previously published reference change value (RCV) of 54.5% [12] derived from the estimate of monoclonal FLC variability in patients with plasma cell disorders as the tolerance [13] in calculating the Sigma metrics for κ FLC and λ FLC. Of note, the RCV value of 54.5% was chosen because it was comparable to the reported interlaboratory reproducibility values achieved during the UK National External Quality Assessment Service (UKNEQAS) FLC EQA scheme (CV of FLC assays was >50%, and often over 100%) [14] . Continuous data are presented as mean (SD) for normally distributed data and median (range) for nonnormally distributed data. Categorical data are presented as numbers (%). Normality was assessed using the D'Agostino and Pearson normality tests. Continuous variables were compared by the Mann-Whitney U-test and/ or one-way analysis of variance for non-normally distributed data and categorical variables were compared by chi-squared (χ 2 ) tests. MedCalc version 14.12.0 (MedCalc Software, Mariakerke, Belgium) was used for statistical analyses. A p-value < 0.05 was considered statistically significant.
This study was conducted in accordance with the ethical guidelines of the Declaration of Helsinki and was approved by the Institutional Review Board (IRB)/ Ethics Committee of Seoul St. Mary's Hospital (IRB No. KC10SISI0037).
Results
Nineteen to 29 laboratories participated in the EQA survey. All participating laboratories used the FLC Freelite ® kits manufactured by Binding Site. Nephelometric (20%) and turbidimetric (80%) methods were used for the FLC assay, and different instruments including Siemens BNII (Siemens Healthineers, Deerfield, IL, USA), Siemens BN-Prospec (Siemens Healthineers), Roche Modular P (Roche, Mannheim, Germany), Hitachi analyzers (Hitachi, Tokyo, Japan), Toshiba (Toshiba, Tokyo, Japan), Siemens Advia 1650 (Siemens Healthineers) and Binding Site SPAPLUS (Binding Site) were used ( Table 2) .
Method-specific total error and Sigma metrics
The method-specific median TE values of κ FLC across 29 EQA specimens were 26% for nephelometry and 25% for turbidimetry. The method-specific median TE values of λ FLC across 29 EQA specimens were 24% and 19% for nephelometry and turbidimetry, respectively.
As the Sigma metric is inversely proportional to CV peer group and EQA distributions with low FLC concentrations (less than the lower limit of the reference interval) are associated with a disproportionately large CV peer group , three κ FLC and three λ FLC EQA distributions with low FLC concentrations were not included in the Sigma metrics analysis. The method-specific median Sigma metrics of κ FLC across 29 EQA specimens were 4.9 for nephelometric methods and 4.9 for turbidimetric methods. The methodspecific median Sigma metrics of λ FLC across 29 EQA specimens were 4.9 for nephelometric methods and 5.4 for turbidimetric methods. There were no statistically significant differences in TE and Sigma metrics between turbidimetric methods and nephelometric methods for κ FLC; however, for λ FLC, nephelometric methods showed larger TE and lower Sigma metrics compared with turbidimetric methods (p < 0.05) ( Figure 1 ).
Method harmonization
We compared the median reported results of the nephelometric and turbidimetric methods for each EQA specimen. Due to the small number of laboratories reporting nephelometric results, the Bland-Altman plot was used. The Bland-Altman plot showed that the average of the difference between the nephelometric and turbidimetric EQA event Method/manufacturer S10-02 S11-01 S11-02 S12-01 S12-02 S13-01 S13-02 S14-01 S14-02 S15-01 S15-02 Nephelometry   8  7  6  5  5  4  3  5  4  3  3  Siemens BNII   7  6  5  4  4  4  3  5  4  3  3  Siemens BN-Prospec  1  1  1  1  1  0  0  0  0  0  0   Turbidimetric   12  12  19  19  21  20  21  22  23  24  25  Roche Modular/Hitachi  9  11  16  17  17  17  18  17  18  17  19  Toshiba   1  1  3  2  4  3  3  3  3  4  3  Siemens Advia   1  1  0  0  0  0  0  0  0  0  0  Binding Site SPAplus  0  0  0  0  0  0  1  2  2  3  3   All methods   20  19  25  24  26  24  24  27  27  27  28 EQA, external quality assurance; FLC, free light chain. methods for κ FLC was 7.2 mg/L and for λ FLC was 42.1 mg/L ( Figure 2 ). While the average difference between the two methods for κ FLC can be regarded as insignificant, for λ FLC there seems to be a significant difference between the two methods, and the difference seems to be due to higher λ FLC concentrations that would require a different sample dilution from that of the initial measuring range.
Interlaboratory reproducibility
The method-specific median interlaboratory reproducibility (CV) of κ FLC across 32 EQA specimens was 12% for both nephelometric and turbidimetric methods. The method-specific median interlaboratory reproducibility of λ FLC across 32 EQA specimens was 12% and 10% for the nephelometric and turbidimetric methods, respectively ( Table 3 ).
The κ FLC and λ FLC values in healthy individuals occur at the lower end of the measuring range, within the manufacturer's reference intervals of 3-19 mg/L for κ FLC and 6-26 mg/L for λ FLC. FLC concentrations that border on the upper reference limit of the reference interval (medical decision point) could potentially be misclassified as normal or abnormal, and discordant results could occur by simply repeating the assay on those samples. E15-02 S10-02-1 S10-02-2 S10-02-3 S11-01-1 S11-01-2 S11-02-1 S11-02-2 S11-02-3 S12-01-1 S12-01-2 S12-01-3 S12-02-1 S12-02-2 S13-01-1 S13-01-2 S13-02-1 S13-02-2 S13-02-3 S14-01-1 S14-01-2 S14-01-3 S14-02-2 S14-02-3 S15-01-1 S15-01-2 S15-01-3 S15-02-1 S15-02-2 S15-02-3 E15-02 S10-02-1 S10-02-2 S10-02-3 S11-01-1 S11-01-2 S11-02-1 S11-02-2 S12-01-1 S12-01-2 S12-02-1 S12-02-2 S12-02-3 S13-01-1 S13-01-2 S13-01-3 S13-02-1 S13-02-2 S13-02-3 S14-01-1 S14-01-3 S14-02-1 S14-02-2 S14-02-3 S15-01-1 S15-01-2 S15-01-3 S15-02-1 S15-02-2 S15-02-3 Regarding interlaboratory reproducibility at values closest to the medical decision point, four EQA specimens had weighted average values near the κ or λ medical decision points. The all-method interlaboratory reproducibility values (CV) were 8%, 14% and 9% at κ FLC concentrations of 17.5, 18.6 and 16.4 mg/L, respectively, and 9% at a λ FLC concentration of 23.7 mg/L.
Nephelometry
Discussion
The FLC assay is extensively used for the diagnosis, prognostic assessment and management of patients with monoclonal gammopathy. The assay can be used on several types of automated analyzers and has been adopted for use in many laboratories nationwide in Korea as an indispensable resource. However, as with any clinical laboratory test, EQA (also known as proficiency testing) is considered a mandatory component of a laboratory quality system [15] . National EQA schemes for the FLC assay have been developed and implemented in France, United Kingdom and Czech [16] , and a number of international schemes also exist. The lack of a national EQA scheme in Korea prompted the development and implementation of an EQA survey for the FLC assay in collaboration with the Quality Assurance Committee of the Korean Society for Laboratory Medicine. There have been more than 30 distributions over a 6-year period, and over 35 laboratories nationwide participated in the scheme.
In this retrospective analysis of the EQA scheme, we applied clinically relevant quality specifications using Sigma metrics. Sigma metrics combine bias, imprecision and the allowable TE and convert them into an overall assessment of the analytical quality of the test [15] . For that purpose, the previously described Sigma Proficiency Assessment Chart was used [9] .
However, due to the lack of a well-established consensus definition of quality requirement regarding the FLC assay, multiple surrogate definitions of quality requirements, including those based on biological variations [12, 17, 18] and/or measurement uncertainties [1] , were assessed. We chose a reported RCV value of 54.5% derived from the estimate of monoclonal FLC variability in patients with plasma cell disorders [12] and applied as tolerance limits in calculating the Sigma metrics for κ FLC and λ FLC. We acknowledge the limitations of using an RCV value as a quality specification as it does not have component for bias and therefore may not be an appropriate substitute for an allowable TE. Moreover, an RCV value of 54.5%, which is derived from the estimate of monoclonal FLC variability in patients with plasma cell disorders, is much larger than reported biological variation of FLC in healthy individuals. However, FLC is clinically a tumor marker and typically in myeloma the monoclonal FLC levels are variably increased above the upper limit of the reference interval. Therefore, a biological variationbased quality requirement may not be a clinically relevant quality specification for the FLC assay. In this regard, the RCV value of 54.5% was chosen because it was comparable to the reported interlaboratory reproducibility values achieved during the UKNEQAS FLC EQA scheme [14] and was similar to a clinical cut-point of 50% FLC reduction defining a clinically relevant FLC response reported in a previous clinical recommendation [10] .
The method-specific Sigma metrics of κ and λ FLC achieved greater than Three-Sigma for 86-97% of all EQA distributions, and the higher quality specifications consistent with Five-Sigma, beyond which little improvement to quality can be achieved [11] , was achieved in 48% of all κ FLC EQA distributions, for the nephelometric and turbidimetric methods, respectively, and 48% and 72% of all λ FLC EQA distributions for the nephelometric and turbidimetric methods, respectively. When only EQA distributions with consensus κ and λ FLC values in the vicinity of κ or λ medical decision points were considered, the method-specific Sigma metrics of κ and λ FLC achieved greater than Three-Sigma for all EQA distributions for both methods, and Five-Sigma was achieved in 67% and 100% of all κ and λ FLC EQA distributions, for the nephelometric and turbidimetric methods, respectively.
We also assessed the harmonization of results between the nephelometric and turbidimetric methods. While the average difference between the two methods is not significant for κ FLC, for λ FLC, the Bland-Altman plot showed a significant difference between the two methods at higher λ FLC concentrations that require a different sample dilution from that of the initial measuring range. This is not surprising as significant method-specific differences in FLC concentrations have been previously reported [14] . Hence, despite the use of the same source of commercial reagent, values were not completely harmonized between assay systems that use different method principles. Possible causes of discordant results between methods include different reaction times, differences in the antigen (sample)/antibody (reagent) ratio in the reaction mixture, different concentrations of polyethylene glycol, different sample dilution protocol and different linearity. The positive difference in nephelometry at higher λ FLC concentrations demonstrated in this study should be investigated further in a larger number of samples.
The method-specific median interlaboratory reproducibility (CV) of κ FLC and λ FLC across 32 EQA specimens ranged from 10 to 12% for both the nephelometric and turbidimetric methods. Interlaboratory reproducibility values reported in this survey were considered acceptable for clinical practice and were better than those achieved during the UK NEQAS external control cycles. Moreover, EQA specimens that had consensus values in the vicinity of κ or λ medical decision points achieved an all-method interlaboratory reproducibility value (CV) of 8-14%, which may be larger than, but not significantly different from, the manufacturer's predetermined acceptance criteria of total precision (%CV < 8.5%) and betweeninstrument precision (%CV < 8.5%), for a relatively narrow FLC concentration range without the need for serum dilution [19] .
EQA provides an essential tool for medical laboratories for evaluating assay performances and establishing quality standards [20] . During the 6-year EQA survey, we found that most of the results from participating laboratories meet clinically relevant quality specifications. We could also provide an estimate of the interlaboratory variability in the FLC assay that participants and physicians should be aware of. In addition, we have highlighted the method-specific differences for λ FLC and also how they tend to increase with increasing FLC concentrations. This may have the potential to mislead clinical assessment of the FLC assay results when serial FLC results involving different methods are used.
There are acknowledged limitations of this study. First, the small number of participating laboratories comprising the nephelometric method subgroup may have introduced bias in the estimation of method-specific performance, despite the use of a weighted average. Second, due to the lack of a well-established consensus definition of quality requirement regarding the FLC assay, a reported RCV value of 54.5% derived from the estimate of monoclonal FLC variability in patients with plasma cell disorders was applied as the tolerance limit in calculating the Sigma metrics. Lastly, as a reference measurement procedure or certified reference material is not available for FLC, we could not assess the reported results of the EQA scheme with reference to trueness.
Despite these limitations, the data collected by the first national EQA scheme for the FLC assay in Korea represent a unique resource for clinical laboratories. We used Sigma metrics and a clinically relevant tolerance limit in analyzing the FLC EQA scheme. The study also shows that between-method differences still exit, and further standardization and harmonization efforts are necessary.
